Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Further details about the exact facilities that will receive the investment weren ... AstraZeneca also pre-released one of ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Yale physicist Eduardo H. da Silva Neto led an experiment that supports the existence of a new type of superconductor.

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. Shares of Exact ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.